Αποτελέσματα Αναζήτησης
Further Biologics in Atopic Dermatitis’ Treatment. In addition to IL-4 and IL-13, other cytokines have been identified to play an important role in the pathophysiology of chronic inflammatory skin disease.
- Treatment of Atopic Dermatitis with Biologic Drugs - PMC
In this review, we discuss all of the biologic drugs that...
- Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Dupilumab, the first biologic drug approved for AD, filled a...
- Biological therapies for atopic dermatitis: An update - PMC
We reviewed the different biological treatments with a focus...
- Biological Therapies for Atopic Dermatitis: A Systematic Review
The biological therapies with the most robust evidence on...
- Treatment of Atopic Dermatitis with Biologic Drugs - PMC
In this review, we discuss all of the biologic drugs that have been studied for AD treatment. Keywords: Atopic dermatitis, Biologic drug, Biologics, Therapy, Treatment. Introduction. Atopic dermatitis (AD) is the most common inflammatory skin disease of childhood, affecting about 20% of children . AD usually resolves before adolescence.
30 Δεκ 2020 · Dupilumab, the first biologic drug approved for AD, filled a large void for a safe and effective therapy for long-term use. Since the advent of dupilumab, several biologics are now being developed and investigated to provide alternatives to dupilumab (Table 1).
19 Νοε 2018 · We reviewed the different biological treatments with a focus on novel targeted agents: Systemic immunotherapy (Omalizumab, Dupilumab, Lebrikizumab, Tralokinumab, Nemolizumab, Ustekinumab, Fezakinumab, Tezepelumab, Apremilast, allergen specific immunotherapy), and topical agents (Tofacitinib, Crisaborole).
4 Οκτ 2024 · Despite therapeutic advancements, a considerable group of atopic dermatitis (AD) patients remains difficult to manage, underscoring the need for novel therapies that can serve as effective alternatives for non-responders or those with only partial response to existing treatments.
The biological therapies with the most robust evidence on efficacy and long-term safety for AD treatment include dupilumab, barcitinib, abrocitinib, and delgocitinib. Most of the biologics mentioned in this review were still at the exploratory stage.
30 Μαΐ 2021 · Dupilumab, an IL-4 and IL-13 inhibitor, was the first biological drug approved by the FDA for the treatment of AD in adults [ 8 ]. It is noteworthy for its acceptable low side effect profile (lower rate of conjunctivitis, injection-site reactions, and infections) and high efficacy (36%-44% of patients achieve clear or almost clear skin) [ 9 – 11 ].
